248 related articles for article (PubMed ID: 24212441)
21. A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.
Pacilio M; Ventroni G; Cassano B; Ialongo P; Lorenzon L; Di Castro E; Recine F; Sternberg CN; Mango L
Ann Nucl Med; 2016 Feb; 30(2):163-8. PubMed ID: 26613714
[TBL] [Abstract][Full Text] [Related]
22. Radionuclide therapy for osseous metastases in prostate cancer.
Abi-Ghanem AS; McGrath MA; Jacene HA
Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
[TBL] [Abstract][Full Text] [Related]
23. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases.
Nilsson S; Larsen RH; Fosså SD; Balteskard L; Borch KW; Westlin JE; Salberg G; Bruland OS
Clin Cancer Res; 2005 Jun; 11(12):4451-9. PubMed ID: 15958630
[TBL] [Abstract][Full Text] [Related]
24. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
25. Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.
Malamas AS; Gameiro SR; Knudson KM; Hodge JW
Oncotarget; 2016 Dec; 7(52):86937-86947. PubMed ID: 27893426
[TBL] [Abstract][Full Text] [Related]
26. Emerging role of Radium-223 in the growing therapeutic armamentarium of metastatic castration-resistant prostate cancer.
Picciotto M; Franchina T; Russo A; Ricciardi GRR; Provazza G; Sava S; Baldari S; Caffo O; Adamo V
Expert Opin Pharmacother; 2017 Jun; 18(9):899-908. PubMed ID: 28449621
[TBL] [Abstract][Full Text] [Related]
27. Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options.
Gartrell BA; Coleman R; Efstathiou E; Fizazi K; Logothetis CJ; Smith MR; Sonpavde G; Sartor O; Saad F
Eur Urol; 2015 Nov; 68(5):850-8. PubMed ID: 26153564
[TBL] [Abstract][Full Text] [Related]
28. Review of Radium-223 and Metastatic Castration-Sensitive Prostate Cancer.
Dandapani SV; Wong J; Twardowski P
Cancer Biother Radiopharm; 2020 Sep; 35(7):490-496. PubMed ID: 32762539
[No Abstract] [Full Text] [Related]
29. Alpha-emitter radium-223 in the management of solid tumors: current status and future directions.
Nilsson S
Am Soc Clin Oncol Educ Book; 2014; ():e132-9. PubMed ID: 24857093
[TBL] [Abstract][Full Text] [Related]
30. Radium Ra 223 dichloride in castration-resistant prostate cancer.
Joung JY; Ha YS; Kim IY
Drugs Today (Barc); 2013 Aug; 49(8):483-90. PubMed ID: 23977665
[TBL] [Abstract][Full Text] [Related]
31. Radiation-based approaches for therapy and palliation of advanced prostate cancer.
Lewis B; Sartor O
Curr Opin Urol; 2012 May; 22(3):183-9. PubMed ID: 22453334
[TBL] [Abstract][Full Text] [Related]
32. The Relationship Between Total Lesion Activity on
Filippi L; Basile P; Schillaci O; Bagni O
Cancer Biother Radiopharm; 2020 Aug; 35(6):398-403. PubMed ID: 32109140
[TBL] [Abstract][Full Text] [Related]
33. Radium-223 for the treatment of bone metastases in castration-resistant prostate cancer: when and why.
Gallicchio R; Mastrangelo PA; Nardelli A; Mainenti PP; Colasurdo AP; Landriscina M; Guglielmi G; Storto G
Tumori; 2019 Oct; 105(5):367-377. PubMed ID: 31096849
[TBL] [Abstract][Full Text] [Related]
34. Radium-223 dichloride in clinical practice: a review.
Florimonte L; Dellavedova L; Maffioli LS
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1896-909. PubMed ID: 27121689
[TBL] [Abstract][Full Text] [Related]
35. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
[TBL] [Abstract][Full Text] [Related]
36. Tackling the bone with alpha emitters in metastatic castration-resistant prostate cancer patients.
Bellmunt J
Eur Urol; 2013 Feb; 63(2):198-200. PubMed ID: 23062225
[No Abstract] [Full Text] [Related]
37. Radium-223: down to the bone, and less is more.
Chang AJ; Roach M
Oncology (Williston Park); 2012 Apr; 26(4):342, 344. PubMed ID: 22655526
[No Abstract] [Full Text] [Related]
38. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.
Poeppel TD; Handkiewicz-Junak D; Andreeff M; Becherer A; Bockisch A; Fricke E; Geworski L; Heinzel A; Krause BJ; Krause T; Mitterhauser M; Sonnenschein W; Bodei L; Delgado-Bolton RC; Gabriel M
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):824-845. PubMed ID: 29234845
[TBL] [Abstract][Full Text] [Related]
39. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
40. Dosimetry of 223Ra-chloride: dose to normal organs and tissues.
Lassmann M; Nosske D
Eur J Nucl Med Mol Imaging; 2013 Jan; 40(2):207-12. PubMed ID: 23053328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
